Next Article in Journal
Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
Previous Article in Journal
Supervised Physical Therapy and Polymyositis/Dermatomyositis—A Systematic Review of the Literature
Open AccessReview

Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

1
School of Medicine, Georgetown University, Washington, DC 20007, USA
2
School of Medicine, Louisiana State University Shreveport, Shreveport, LA 71103, USA
3
Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA
4
School of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA
5
Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA
6
Department of Neurology, Louisiana State University Shreveport, Shreveport, LA 71103, USA
7
College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85724, USA
8
Department of Anesthesiology, School of Medicine, Creighton University, Omaha, NE 68124, USA
9
Valley Anesthesiology and Pain Consultants—Envision Physician Services, Phoenix, AZ 85004, USA
10
Southcoast Health, Southcoast Physicians Group Pain Medicine, Wareham, MA 02571, USA
*
Author to whom correspondence should be addressed.
Neurol. Int. 2020, 12(3), 89-108; https://doi.org/10.3390/neurolint12030016
Received: 23 October 2020 / Revised: 20 November 2020 / Accepted: 1 December 2020 / Published: 3 December 2020
Multiple sclerosis (MS) is a prevalent and debilitating neurologic condition characterized by widespread neurodegeneration and the formation of focal demyelinating plaques in the central nervous system. Current therapeutic options are complex and attempt to manage acute relapse, modify disease, and manage symptoms. Such therapies often prove insufficient alone and highlight the need for more targeted MS treatments with reduced systemic side effect profiles. Ozanimod is a novel S1P (sphingosine-1-phosphate) receptor modulator used for the treatment of clinically isolated syndrome, relapsing–remitting, and secondary progressive forms of multiple sclerosis. It selectively modulates S1P1 and S1P5 receptors to prevent autoreactive lymphocytes from entering the CNS where they can promote nerve damage and inflammation. Ozanimod was approved by the US Food and Drug Administration (US FDA) for the management of multiple sclerosis in March 2020 and has been proved to be both effective and well tolerated. Of note, ozanimod is associated with the following complications: increased risk of infections, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, and posterior reversible encephalopathy syndrome, among others. Further investigation including head-to-head clinical trials is warranted to evaluate the efficacy of ozanimod compared with other S1P1 receptor modulators. View Full-Text
Keywords: ozanimod; multiple sclerosis; sphingosine-1-phosphate receptor modulator; chronic pain ozanimod; multiple sclerosis; sphingosine-1-phosphate receptor modulator; chronic pain
MDPI and ACS Style

Lassiter, G.; Melancon, C.; Rooney, T.; Murat, A.-M.; Kaye, J.S.; Kaye, A.M.; Kaye, R.J.; Cornett, E.M.; Kaye, A.D.; Shah, R.J.; Viswanath, O.; Urits, I. Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Neurol. Int. 2020, 12, 89-108. https://doi.org/10.3390/neurolint12030016

AMA Style

Lassiter G, Melancon C, Rooney T, Murat A-M, Kaye JS, Kaye AM, Kaye RJ, Cornett EM, Kaye AD, Shah RJ, Viswanath O, Urits I. Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Neurology International. 2020; 12(3):89-108. https://doi.org/10.3390/neurolint12030016

Chicago/Turabian Style

Lassiter, Grace; Melancon, Carlie; Rooney, Tyler; Murat, Anne-Marie; Kaye, Jessica S.; Kaye, Adam M.; Kaye, Rachel J.; Cornett, Elyse M.; Kaye, Alan D.; Shah, Rutvij J.; Viswanath, Omar; Urits, Ivan. 2020. "Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects" Neurol. Int. 12, no. 3: 89-108. https://doi.org/10.3390/neurolint12030016

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop